Table 1.

Anti-GPCR antibodies approved by the US FDA or subject to clinical trial.

Antigen Type	Antibody Screening Technology	Drug Name	Target	Indication	Status of Clinical Trial	Reference
RAMP1-Fc, CGRPR-Fc	Tg mouse immunization and hybridoma screening	AimovigTM (Erenumab)	CGRP receptor	Migraine	Approved	[14]
CCR4-KLH	Mouse immunization and hybridoma screening	Poteligeo® (Mogamulizumab)	CCR4	Refractory mycosis fungoides and Sézary disease	Approved	[15]
FZD7-Fc	Synthetic human antibody phage library screening	Vantictumab (OMP-18R5)	FZD7	Non-small cell lung cancer, pancreatic cancer, metastatic breast cancer	Phase I	[16,17,18]
CCR5 expressing cells	Mouse immunization and hybridoma screening	Leronlimab (Pro 140)	CCR5	HIV infection	Phase III	[19]
CCR2 expressing cells	Mouse immunization and hybridoma screening	Plozalizumab (MLN-1202)	CCR2	Relapsing-remitting multiple sclerosis	Phase II	[20]
CXCR4 expressing cells	Tg mouse immunization and phage library screening	Ulocuplumab (BMS-936564)	CXCR4	Acute myeloid leukemia	Phase I/II	[21]
C5Aa1 expressing cells	Tg mouse immunization and hybridoma screening	Avdoralimab (IPH5401)	C5aR1	Non-small cell lung cancer, liver cancer	Phase I	[22]
Membrane fraction of GLP1R expressing cells	Tg mouse immunization and hybridoma screening	Glutazumab (GMA102)	GLP1R	Type 2 diabetes	Phase II	[23]
Membrane fraction of GCGR expressing cells	Tg mouse immunization and hybridoma screening	Volagidemab (REMD-477)	GCGR	Diabetes mellitus	Phase II	[24]
Reconstituted CNR1 GLB complex	Mouse immunization and hybridoma/phage library screening	Namacizumab (RYI-018)	CNR1	Non-alcoholic fatty liver disease	Phase I	[25]